Trials / Completed
CompletedNCT03042416
18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 400 (actual)
- Sponsor
- University of Alberta · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Single centre prospective cohort phase III study of 18F-DOPA PET/CT imaging in specific patient populations: 1. Pediatric patients with congenital hyperinsulinism 2. Pediatric patients with neuroblastoma 3. Pediatric or Adult patients with suspected extra-pancreatic neuroendocrine tumor 4. Adult patients with a clinical suspicion of Parkinson's disease 5. Pediatric or Adult patients with primary brain tumors This study will evaluate the biodistribution and safety of 18F-DOPA produced at the Edmonton PET Centre.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 18F-DOPA | 18F-DOPA intravenous injection single dose |
Timeline
- Start date
- 2017-06-29
- Primary completion
- 2021-03-05
- Completion
- 2021-06-02
- First posted
- 2017-02-03
- Last updated
- 2022-01-10
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT03042416. Inclusion in this directory is not an endorsement.